See if CXCR4 PET imaging helps diagnose and predict outcomes for lymphoproliferative diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, early-phase study uses 68Ga-Pentixafor PET/CT to measure CXCR4 expression in patients with suspected or untreated lymphoproliferative diseases. The goal is to determine if metabolic imaging of CXCR4 can improve diagnostic accuracy, risk stratification, and prognostic assessment beyond standard methods. Participants will undergo 18F-FDG PET/CT within two weeks prior to enrollment and receive the CXCR4-targeted PET/CT as part of the evaluation. The study focuses on lymphoma subtypes, multiple myeloma, and leukemia, with an emphasis on CXCR4 expression as a biomarker. Outcomes include correlation with disease characteristics and potential implications for patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* suspected or confirmed untreated Lymphoproliferative diseases patients
* 18F-FDG PET/CT within two weeks
* signed written consent.

Exclusion Criteria:

* pregnancy
* breastfeeding
* known allergy against Pentixafor

Where it's running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Weibing Miao, M.D. — First Affiliated Hospital of Fujian Medical University
• Study coordinator: Weibing Miao, M.D.
• Email: miaoweibing@126.com
• Phone: +86-599-87981618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

  This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT07205523

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Using a NEWS early warning score to prompt ICU admission for adults receiving intensive chemotherapy or stem cell transplant

  This trial tests whether real-time monitoring with the NEWS early warning score and prompt ICU admission (NEWS ≥ 7) helps adults with leukemia, lymphoma, or multiple myeloma who are receiving intensive chemotherapy or a hematopoietic cell transplant.

  Recruiting at 9 sites University Hospital, Angers · Amiens and 9 other locations · NCT06409767

• Evaluating a decision support tool for patients with blood cancers

  This study tests a new tool called PRIME to see if it helps older adults with blood cancers make treatment choices that better match their personal preferences compared to regular care.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06296368

• Return to Work After Hematologic Cancer

  This study tests whether a dedicated return-to-work consultation helps adults with blood cancers who finished treatment to go back to their jobs.

  Recruiting at 4 sites University Hospital, Angers · Angers and 9 other locations · NCT06262789

• Improving quality of life for blood cancer patients receiving cellular therapy

  This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05646576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.